Early-Frame [F]Florbetaben PET/MRI for Cerebral Blood Flow Quantification in Patients with Cognitive Impairment: Comparison to an [O]Water Gold Standard.

Cerebral blood flow (CBF) may be estimated from early-frame PET imaging of lipophilic tracers, such as amyloid agents, enabling measurement of this important biomarker in participants with dementia and memory decline. Although previous methods could map relative CBF, quantitative measurement in absolute units (mL/100 g/min) remained challenging and has not been evaluated against the gold standard method of [O]water PET. The purpose of this study was to develop and validate a minimally invasive quantitative CBF imaging method combining early [F]florbetaben (eFBB) with phase-contrast MRI using simultaneous PET/MRI.